Alembic Pharmaceuticals moves up as its partner NATCO gets USFDA`s tentative nod for Olaparib Tablets
Alembic Pharmaceuticals is currently trading at Rs. 829.25, up by 3.90 points or 0.47% from its previous closing of Rs. 825.35 on the BSE.
The scrip opened at Rs. 834.60 and has touched a high and low of Rs. 837.55 and Rs. 828.80 respectively. So far 1666 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1064.70 on 21-Jul-2025 and a 52 week low of Rs. 635.30 on 23-Mar-2026.
Last one week high and low of the scrip stood at Rs. 855.70 and Rs. 813.65 respectively. The current market cap of the company is Rs. 16413.02 crore.
The promoters holding in the company stood at 69.87%, while Institutions and Non-Institutions held 20.12% and 10.01% respectively.
Alembic Pharmaceuticals’ partner NATCO Pharma (NATCO) has received tentative approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Olaparib Tablets, 100 mg and 150 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Lynparza Tablets, 100 mg and 150 mg, of AstraZeneca Pharmaceuticals LP (AstraZeneca) for the indication in the approved labelling. The company will distribute the product in the U.S., and its partner NATCO will manufacture Olaparib Tablets, 100 mg and 150 mg.
The Para IV litigation is on-going. Olaparib Tablets, 100 mg and 150 mg, have an estimated market size of around $1.4 billion in the U.S. for twelve months ending March 2026, according to IQVIA. The company has a cumulative total of 244 ANDA approvals (224 final approvals and 20 tentative approvals) from USFDA.
